Antiviral Agents against Flavivirus Protease: Prospect and Future Direction

20Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Flaviviruses cause a significant amount of mortality and morbidity, especially in regions where they are endemic. A recent example is the outbreak of Zika virus throughout the world. Development of antiviral drugs against different viral targets is as important as the development of vaccines. During viral replication, a single polyprotein precursor (PP) is produced and further cleaved into individual proteins by a viral NS2B-NS3 protease complex together with host proteases. Flavivirus protease is one of the most attractive targets for development of therapeutic antivirals because it is essential for viral PP processing, leading to active viral proteins. In this review, we have summarized recent development in drug discovery targeting the NS2B-NS3 protease of flaviviruses, especially Zika, dengue, and West Nile viruses.

Cite

CITATION STYLE

APA

Samrat, S. K., Xu, J., Li, Z., Zhou, J., & Li, H. (2022, March 1). Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens. MDPI. https://doi.org/10.3390/pathogens11030293

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free